Study period Total sample size (% women) 899 (37.7%) Warfarin Aspirin
|
|
- Carol Sherman
- 5 years ago
- Views:
Transcription
1 Table S2 Sex- specific differences in oral anticoagulant prescription for stroke prevention in AF Total sample size (% women) Anticoagulant(s) studied Gage (2000) 1 Missouri, USA Discharged during 597 (54.9%) Warfarin Oct 1993 Aspirin Medicare Dec 1994 beneficiaries with chronic nonvalvular AF at Missouri hospitals Overall antithrombotic : Warfarin: 34% Aspirin: 21% Neither: 45% Women: Warfarin: 29% Aspirin: 21% Humphries (2001) 2 CARAF Six cities across Canada Patients recruited at physicians offices, emergency departments, and during hospital admission at first ECG- confirmed diagnosis of AF Enrolment during (37.7%) Warfarin Aspirin Women less likely to receive antithrombotic than men (P = 0.02) Women aged 75 years were less likely to receive warfarin but more likely to receive aspirin than men aged 75 years. There was a significant interaction between age 75 years and sex for antithrombotic use (P = for interaction) Among patients aged 75 years with 1 stroke risk factor, men (44.9%) more likely to be receiving warfarin than women (24.5%; P = 0.034) Page 1 of 9
2 Simpson (2005) 3 Scotland (61 primary care practices) Walker (2008) 4 Niska (2009) 5 Patients with computer record of transient cerebral ischaemia or any stroke, including cerebral infarction and other stroke USA Patients aged 40 years with AF or atrial flutter covered for both medical and pharmacy services by a large health plan USA Patients with AF aged 20 years randomly sampled from 112 geographical primary sampling units Implementation of secondary preventive between March 2003 and April 2004 Insurance claim during January 1999 June 2005 Visit files during ,076 (52.4%) Warfarin Antiplatelet 116,969 (41.0%) Warfarin Antiplatelet 1,171 (47.9%) Warfarin Aspirin Page 2 of 9 Overall 76.8% of patients with ischaemic stroke patients received either antiplatelet or warfarin Women with ischaemic stroke were less likely to receive either an antiplatelet or warfarin than men (OR 0.84, 95% CI ) Women with AF were less likely to receive warfarin (OR 0.62, 95% CI ) and more likely to receive antiplatelet than men (OR 1.30, 95% CI ) Overall antithrombotic : Warfarin: 45% Antiplatelet: 6% Neither: 48% Men were more likely to be dispensed an anticoagulant than women (OR 1.46, 95% CI ) Overall antithrombotic : Warfarin: 52.2% Aspirin: 15.9% Women less likely to be prescribed warfarin than men (OR 0.69, 95% CI )
3 Agarwal (2010) 6 USA In- patients aged 40 years diagnosed with AF during hospitalization, from approximately 250 hospitals Hospitalization between November 2003 and October ,193 (51.5%) Warfarin Unfractionated heparin Low- molecular heparin Overall warfarin use: 56.2% Women less likely to receive warfarin (OR 0.96, 95% CI , P = ) No sex- specific differences for warfarin use in patients aged 75 years (OR 0.95, 95% CI , P = ) Inoue (2010) 7 J- TRACE 10 regions in Japan Patients aged years with at least 1 3 cardiovascular diseases (stroke, MI, or AF) January 2005 December ,892 (29.9%) Warfarin Antiplatelet (aspirin, ticlopidine, cilostazol) Women less likely to receive other anticoagulants (OR 0.93, 95% CI , P = ) No sex- specific differences in the use of warfarin at baseline Women: 72.7% Men: 73.1% P = No sex- specific differences in the use of aspirin, ticlopidine, cilostazol at baseline Women: 30.8%, 5.0%, 1.3% Men: 32.1%, 5.0%, 2.0% P = 0.504, 0.316, Page 3 of 9
4 Sjolander (2012) 8 Raji (2013) 9 Lee (2015) 10 Sweden Patients with ischaemic stroke from the Swedish Stroke Register with information on prescription of secondary preventive drugs USA Medicare beneficiaries aged 65 years with AF and atrial flutter South Korea Patients with AF or atrial flutter and high risk of thromboembolism (CHADS 2 2) from the Korean Health Insurance Service July 2005 June ,349 (49.1%) Warfarin Antiplatelet Men more likely to be prescribed warfarin than women (38.4% vs 26.4%; age- adjusted prevalence ratio 0.88, 95% CI ) No sex- specific differences in antiplatelet treatment (men 81.3%, women 82.6%; age- adjusted prevalence ratio % CI ) ,447 (60.4%) Warfarin Overall warfarin use: 66.8% Women: 65.6% Men: 68.7% P < ,475 (48.6%) Warfarin Aspirin No sex- specific difference for warfarin use after multivariable adjustment (OR 1.04, 95% CI ) Women more likely to underutilize warfarin* (OR 1.27, 95% , P <0.0001) No sex- specific difference for aspirin* underutilization (adjusted OR 1.09, 95% CI , P = ) Page 4 of 9
5 Lip (2015) 11 GARFIELD- AF 30 countries (Europe, Asia, Central/South America, Canada, Australia, South Africa) Aged 18 years with nonvalvular AF and 1 additional factor(s) for stroke Enrolment during March 2010 June 2013 Total sample size (% women) 17,184 (43.8%) Europe 63.1% Asia 23.0% Central/South America 8.4% Canada 2.0% Australia 2.5% South Africa 1.0% Anticoagulant(s) studied Vitamin K antagonists Oral, injectable, or undefined factor Xa inhibitors Direct thrombin inhibitors Overall rate of use similar in women (60.8%) and men (60.0%) Rate of NOAC use similar in women (11.7%) and men (11.8%) Rate of antiplatelet use alone similar in women (27.2%) and men (28.0%) For women with CHA 2 DS 2 - VASc = 1 (41.1%) and men with CHA 2 DS 2 - VASc=0 (41.8%) the rate of anticoagulant use was similar For women (64.6%) and men (61.6%) with CHA 2 DS 2 - VASc = 2, the rate of anticoagulant use was similar Among patients with CHADS 2 2, anticoagulant use was similar in women and men (OR 1.00, 95% CI ) Page 5 of 9
6 Patel (2015) 12 GWTG- STROKE Olesen (2015) 13 1,542 hospitals in the USA Patients with AF hospitalized for ischaemic stroke (79.1%) or TIA (20.9%) and discharged receiving warfarin or NOAC Denmark, nationwide OAC- naive patients with AF, aged years, who were initiated on OAC Discharged during October 2010 September 2012 Initiated on OAC during August 2011 October ,655 (53.1%) Dabigatran Rivaroxaban Warfarin 18,611 (45.3%) Vitamin K antagonists Dabigatran Rivaroxaban Apixaban Overall OAC use: Warfarin: 88.9% Dabigatran: 9.6% Rivaroxaban: 1.5% Women: Dabigatran or rivaroxaban: 51.8% Warfarin: 53.3% No difference in the discharge prescription of dabigatran or rivaroxaban vs warfarin between women and men (OR for women vs men 0.94, 95% CI , P = 0.1) Overall OAC use: Warfarin: 53.2% Dabigatran: 38.3% Rivaroxaban: 7.0% Apixaban: 1.5% Women: Warfarin: 43.4% Dabigatran: 46.5% Rivaroxaban: 52.1% Apixaban: 51.1% P <0.001 Men less likely to be prescribed NOAC than women (OR 0.88, 95% CI , P <0.001) Page 6 of 9
7 Avgil Tsadok Quebec, Canada (2015) 14 Patients discharged after hospitalization with diagnosis of AF Discharged during January 1999 March ,110 (50.4%) Dabigatran Warfarin Dabigatran 110 mg Women: 64.8% Men: 48.2% Dabigatran 110 mg Aged <75 years: Women: 22.8% Men: 18.5% Aged >75 years: Women: 83.5% Men: 76.0% Hsu (2016) 15 PINNACLE USA, nationwide, office- based Patients with AF and CHADS 2 score 2 or CHA 2 DS 2 - VASc score 2 who are receiving aspirin or oral anticoagulation Enrolment during January 2008 December 2012 CHADS 2 score 2: 210,380 (46%) CHA 2 DS 2 - VASc score 2: 294,642 (46%) Warfarin NOAC Women more likely to receive dabigatran 110 mg compared with men even after adjusting for age and baseline comorbidities (OR 1.35, 95% CI ) CHADS 2 score 2: Men more likely to receive OAC than aspirin compared with women (RR of aspirin vs OAC for men 0.93, 95% CI ) CHA 2 DS 2 - VASc score 2: Men more likely to receive OAC than aspirin compared to women (RR of aspirin vs OAC for men 0.91, 95% CI ) Page 7 of 9
8 Bo (2016) 16 Italy Patients aged 65 years with primary or secondary AF at a single hospital in Turin Discharged during ,078 (60.3%) Vitamin K antagonists Female sex not a significant factor for warfarin prescription in univariate analysis *Warfarin and aspirin underutilization defined as never having been prescribed warfarin or aspirin, respectively, if the patient has a CHADS 2 score 2. AF, atrial fibrillation; ECG, electrocardiogram; MI, myocardial infarction; NOAC, non- vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; TIA, transient ischaemic attack. 1. Gage, B. F. et al. Adverse outcomes and predictors of underuse of antithrombotic in medicare beneficiaries with chronic atrial fibrillation. Stroke 31, (2000). 2. Humphries, K. H. et al. New- onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 103, (2001). 3. Simpson, C. R., Wilson, C., Hannaford, P. C. & Williams, D. Evidence for age and sex differences in the secondary prevention of stroke in Scottish primary care. Stroke 36, (2005). 4. Walker, A. M. & Bennett, D. Epidemiology and outcomes in patients with atrial fibrillation in the United States. Heart Rhythm 5, (2008). 5. Niska, R. & Han, B. Anticoagulation for patients with atrial fibrillation in ambulatory care settings. J. Am. Board Fam. Med. 22, (2009). 6. Agarwal, S., Bennett, D. & Smith, D. J. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am. J. Cardiovasc. Drugs 10, (2010). 7. Inoue, H. et al. Sex- related differences in the risk factor profile and medications of patients with atrial fibrillation recruited in J- TRACE. Circ. J. 74, (2010). 8. Sjolander, M., Eriksson, M. & Glader, E. L. Few sex differences in the use of drugs for secondary prevention after stroke: a nationwide observational study. Pharmacoepidemiol. Drug Saf. 21, (2012). 9. Raji, M. A. et al. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population- based study of Medicare Part D beneficiaries. Ann. Pharmacother. 47, (2013). 10. Lee, I. H., Kim, H. & Je, N. K. Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea. J. Cardiol. 66, (2015). 11. Lip, G. Y. et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD- Atrial Fibrillation. Circ. Cardiovasc. Qual. Outcomes 8, S12 S20 (2015). 12. Patel, P. A. et al. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circ. Cardiovasc. Qual. Outcomes 8, (2015). Page 8 of 9
9 13. Olesen, J. B. et al. Non- vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data Europace 17, (2015). 14. Avgil Tsadok, M., Jackevicius, C. A., Rahme, E., Humphries, K. H. & Pilote, L. Sex differences in dabigatran use, safety, and effectiveness in a population- based cohort of patients with atrial fibrillation. Circ. Cardiovasc. Qual. Outcomes 8, (2015). 15. Hsu, J. C. et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J. Am. Coll. Cardiol. 67, (2016). 16. Bo, M. et al. Health status, geriatric syndromes and prescription of oral anticoagulant in elderly medical inpatients with atrial fibrillation. Geriatr. Gerontol. Int. (2016). Page 9 of 9
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationGLORIA -AF REGISTRY PROGRAMME
GLORIA -AF REGISTRY PROGRAMME EXECUTIVE SUMMARY The approval of novel oral anticoagulants has changed prescribing patterns for stroke prevention in atrial fibrillation (AF) worldwide. 1 There is a need
More informationAtrial Fibrillation Implementation challenges. Lesley Edgar Ross Maconachie
Atrial Fibrillation Implementation challenges Lesley Edgar Ross Maconachie Atrial Fibrillation Most common heart rhythm disturbance Rapid and irregular electrical signals Reduced efficiency of blood flow
More informationShow Me the Outcomes!
Show Me the Outcomes! Real-World Safety Data on Oral Anticoagulants in Nonvalvular Atrial Fibrillation Gabby Anderson, PharmD PGY1 Pharmacy Resident anderson.gabrielle@mayo.edu Pharmacy Grand Rounds October
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationRETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
RETROSPECTIVE CLAIMS DATABASE STUDIES OF DIRECT ORAL ANTICOAGULANTS (DOACS) FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION Craig I. Coleman, PharmD Professor, University of Connecticut School
More informationTrends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation,
Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017 Junya Zhu, PhD Department of Health Policy and Management January 23, 2018 Acknowledgments Co-Authors G.
More informationStroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University
Stroke Prevention in AF: How will it change in the next 5 years? Jeff Healey MD, MSc, FHRS Population Health Research Institute McMaster University Disclosures Research Grants and speaking fees St. Jude
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationEvaluate Risk of Stroke & Bleeding in AF Patients
XV World Congress of Arrhythmias, Beijing, China - 17-20 September, 2015 Evaluate Risk of Stroke & Bleeding in AF Patients Antonio Raviele, MD, FESC, FHRS President ALFA Alliance to Fight Atrial fibrillation
More informationADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE
ADDRESSING UNMET NEEDS IN MANAGING AF ACROSS THE GLOBE HELEN WILLIAMS FFRPS, MRPHARMS, PGDIP (CARDIOL) IPRESC CONSULTANT PHARMACIST FOR CVD, SOUTH LONDON CLINICAL LEAD FOR ATRIAL FIBRILLATION, HEALTH INNOVATION
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process
Quality ID #326 (NQF 1525): Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Management of Chronic
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationStratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto
Fibrillazione atriale: rischio tromboembolico, Venezia - 27/28 Novembre 2015 Stratificazione del rischio, corretto bilancio tra ischemia e bleeding: il beneficio clinico netto Antonio Raviele, MD, FESC,
More informationSUPPLEMENTAL MATERIALS
SUPPLEMENTAL MATERIALS Table S1: Variables included in the propensity-score matching Table S1.1: Components of the CHA 2DS 2Vasc score Table S2: Crude event rates in the compared AF patient cohorts Table
More informationTransient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction
Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction Doron Aronson MD, Gregory Telman MD, Fadel BahouthMD, Jonathan Lessick MD, DSc and Rema Bishara MD Department of Cardiology
More informationReducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA
DECEMBER 21 VOL. 27 SUPPL. 1 A SUPPLEMENT TO www.fedprac.com Reducing the Risk of Stroke Associated With Nonvalvular Atrial Fibrillation in the VHA Diagnosing and Treating Atrial Fibrillation in the VHA
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationTable S10 Mortality Study
Table S10 Mortality Study Framingham Heart Study, Benjamin (1998) 1 ELAT Study, Austria and Serbia Stollberger (2004) 2 Copenhagen City Heart study, Denmark Friberg (2004) 3 Patel (2004) 4 Invited residents
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationSUPPLEMENTARY INFORMATION
Table S1 Sex- specific differences in rate- control and rhythm- control strategies in observational studies Study region Study period Total sample size Sex- specific results Ozcan (2001) 1 Mayo Clinic,
More informationDefining Sub-Clinical Atrial Fibrillation and its management
Defining Sub-Clinical Atrial Fibrillation and its management Jeff Healey MD, MSc, FRCP, FHRS PHRI Chair in Cardiology Research Population Health Research Institute McMaster University, Canada Sub-Clinical
More informationAnticoagulation, atrial fibrillation in elderly patients with chronic kidney disease
Anticoagulation, atrial fibrillation in elderly patients with chronic kidney disease Zbigniew Heleniak M.D. Ph.D. Department of Nephrology, Transplantology and Internal Medicine Medical University of Gdansk
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationApixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis
Apixaban for Atrial Fibrillation in Patients with End-Stage Renal Disease on Dialysis Caitlin Reedholm, PharmD PGY1 Pharmacy Resident St. David s South Austin Medical Center November 2, 2018 Abbreviations
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationIdentifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated?
Identifying Patients for Anticoagulation: While Many Patients Remain Untreated, Who Should NOT be Anticoagulated? Renato D. Lopes, MD MHS PhD Professor of Medicine Division of Cardiology Duke Clinical
More informationState of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data
State of art in anticoagulation in non valvular Atrial Fibrillation: the additional value of Rivaroxaban real life data Massimo Grimaldi Ospedale F. Miulli Acquaviva delle Fonti - Bari Disclosure Biosense
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationSupplementary Appendix
Supplementary Appendix Increased Risk of Atrial Fibrillation and Thromboembolism in Patients with Severe Psoriasis: a Nationwide Population-based Study Tae-Min Rhee, MD 1, Ji Hyun Lee, MD 2, Eue-Keun Choi,
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationSpontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
More informationDo Not Cite. Draft for Work Group Review.
Defect Free Acute Inpatient Ischemic Stroke Measure Bundle Measure Description Percentage of patients aged 18 years and older with a diagnosis of ischemic stroke OR transient ischemic attack who were admitted
More informationAntithrombotic Therapy in Patients with Atrial Fibrillation
Antithrombotic Therapy in Patients with Atrial Fibrillation June Soo Kim, M.D., Ph.D. Department of Medicine Cardiac & Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine
More informationWhere a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation Nielsen, Peter Brønnum; Skjøth, Flemming; Rasmussen, Lars Hvilsted; Larsen, Torben Bjerregaard; Lip, Gregory DOI: 10.1016/j.cjca.2015.01.034
More informationCurrent state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice
Current state of the art and new horizons for stroke prevention in AF How to Improve Practical Decision-making in Everyday Clinical Practice GREGORY Y H LIP MD FRCP (Lond Edin Glasg] FACC FESC Professor
More informationMY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory
MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation Lip, Gregory DOI: 10.1016/j.tcm.2014.05.012 License: Other (please specify with Rights Statement) Document Version
More informationLeft Atrial Appendage Occlusion
Left Atrial Appendage Occlusion A new strategy to prevent stroke in atrial fibrillation Ashok Talreja MD and Arijit Chanda MD VHVI symposium 24th February 2018 Outline of presentation 1. Risk of stroke
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationStroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher?
Current Controversies 1165 Stroke risk in atrial fibrillation: Do we anticoagulate CHADS 2 or CHA 2 DS 2 -VASc 1, or higher? Jonas Bjerring Olesen 1 ; Christian Torp-Pedersen 2 1 Department of Cardiology,
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationPatients presenting with acute stroke while on DOACs
Patients presenting with acute stroke while on DOACs Vemmos Kostas, MD, PhD Stroke Medicine Hellenic Cardiovascular Research Society Conflicts of interest Honoraria and speaker fees from: BAYER, SANOFI,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Olesen JB, Lip GYH, Kamper A-L, et al. Stroke and bleeding
More informationThe Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke
Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationSurvey patients for Sx, signs of AF. Establish AF Dx. Evaluate & Tx underlying heart disease/other causes. Assess adequacy of rate or rhythm control
Suggested General Approach to Managing Atrial Fibrillation Survey patients for Sx, signs of AF Establish AF Dx ECG Holter Event monitor Implanted device (pacer) Determine & Tx stroke risk (CHA 2 DS 2 VASc)
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationCondition Congestive heart failure I11.0; I13.0; I13.2; I42.0; I50 CO3C Left ventricular dysfunction I50.1; I50.9 E11 1; E11 9
Comparative effectiveness and safety of non-vitamin K antagonists oral anticoagulants (OACs) and warfarin in daily clinical practice: A propensity weighted nationwide cohort study. Supplementary material
More informationDaniela Poli 12 Novembre 2016
Daniela Poli 12 Novembre 2016 Prevalence of AF in relation to age and sex
More informationQuestion 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG:
Atrial Fibrillation in Your Area Question 1: Between 1 July 2014 and 30 June 2015, in the area covered by your CCG: a) What was the prevalence of atrial fibrillation (AF)? 6636 (as of 22/10/2015) 2.1%
More informationSTROKE PREVENTION 5/11/2015. Stroke Incidence by Age. Cardiogenic Embolism is the most common cause of stroke
(%) (%) 5/11/15 STROKE PREVENTION Stroke Incidence by Age T H E G E N E R A L P R A C T I C E E D U C A T I O N D A Y U N I V E R S I T Y O F Q U E E N S L A N D 3 1 O C T O B E R 2 1 5 A S S O C I A T
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Freedman B, Potpara TS, Lip GYH. Stroke prevention
More informationNOAC vs. Warfarin in AF Catheter Ablation
KHRS 2013 2013-Jun-15 NOAC vs. Warfarin in AF Catheter Ablation Jin-Seok Kim, MD Department of Cardiology Sejong General Hospital Bucheon, Republic of Korea Clinical Burden of AF Rhythm Disturbance Thromboembolic
More informationThe Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure?
The Poor Long-Term Candidate for Warfarin: NOAC or Left Atrial Appendage Closure? Suneet Mittal, MD, FACC, FHRS Director, Electrophysiology Laboratory Valley Health System Ridgewood, NJ and New York, NY
More informationThe New Drugs: Are They Worth It? A PHARMACOECONOMIC PERSPECTIVE
The New Drugs: Are They Worth It? A PHARMACOECONOMIC PERSPECTIVE Niteesh K. Choudhry, MD, PhD Associate Professor, Harvard Medical School Associate Physician, Division of Pharmacoepidemiology and Pharmacoeconomics,
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationProf. Fiorenzo Gaita
Adavances in Cardiac Arrhythmias and Great Innovations in Cardiology Turin 2014 Can rhythm control strategy reduce the risk of clinical and silent cerebral ischemia? Prof. Fiorenzo Gaita Director of the
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationEliquis and plavix combination therapy
Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is
More informationPrimary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion. Greg Francisco, MD, FACC
Primary Care Atrial Fibrillation Update: Anticoagulation and Left Atrial Appendage Occlusion Greg Francisco, MD, FACC DISCLOSURES None to declare Estimated 33.5million have AF worldwide (6-7million in
More informationWeighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated?
Weighing the risk of stroke vs the risk of bleeding: Which AF patients should be anticoagulated? Albert L. Waldo, MD, PhD (Hon) The Walter H. Pritchard Professor of Cardiology, Professor of Medicine,and
More informationMohammad Zubaid, MB, ChB, FRCPC, FACC
Management and one year outcome of atrial fibrillation in Middle Eastern cohort enrolled in the observational Gulf Survey of Atrial Fibrillation Events (Gulf SAFE) Mohammad Zubaid, MB, ChB, FRCPC, FACC
More informationDrug Class Review Newer Oral Anticoagulant Drugs
Drug Class Review Newer Oral Anticoagulant Drugs Final Original Report May 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationDraft Agreed by Cardiovascular Working Party 25 Jan Adoption by CHMP for release for consultation 17 Feb 2011
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 London, 25 January 2011 EMA/CHMP/68875/2011 Committee for Medicinal Products for Human Use (CHMP) Concept paper on the need for a guideline on clinical investigation
More informationNEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION
NEW APPROACHES AND NEW ANTICOAGULANTS FOR ATRIAL FIBRILLATION MAY 1, 2015 Melissa R. Robinson, MD FACC FHRS CCDS Assistant Professor of Medicine Director of the Complex Arrhythmia Service POINTS TO MAKE
More informationEach year in the United States, approximately men and
Circulation: Cardiovascular Quality and Outcomes Topic Review Most Important Outcomes Research Papers on Stroke and Transient Ischemic Attack Rachel Dreyer, PhD; Karthik Murugiah, MD; Sudhakar V. Nuti,
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More informationNOACs in AF. Dr Fiona Stewart. Auckland Heart Group and Auckland DHB
NOACs in AF Dr Fiona Stewart Auckland Heart Group and Auckland DHB NOACS for AF True/False All patients should have a CHA 2 DS 2 VASc risk assessment on diagnosis of AF NOACS are more effective than warfarin
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationATRIAL FIBRILLATION AROUND THE WORLD/ CONTINENTAL PERSPECTIVES AND SPECIFICITIES: SOUTH AMERICA. LUIS AGUINAGA MD, PhD, FESC,FACC Argentina
ATRIAL FIBRILLATION AROUND THE WORLD/ CONTINENTAL PERSPECTIVES AND SPECIFICITIES: SOUTH AMERICA LUIS AGUINAGA MD, PhD, FESC,FACC Argentina 2010 Global Burden of Disease Study Chugh, S. S. et al. Circulation,
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationPeer Review Report #2. Novel oral anticoagulants. (1) Does the application adequately address the issue of the public health need for the medicine?
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report #2 vel oral anticoagulants (1) Does the application adequately address the issue of the public health need for the
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationManuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de
When not to exclude the LAA Manuel Castellá Cardiovascular Surgery Hospital Clínic, Universidad de Barcelona mcaste@clinic.ub.es @mcastellamd Normal hearts Patient in sinus rhythm Patient in AF (with
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationEpidemiology current status: heart and brain
Epidemiology current status: heart and brain Veikko Salomaa, MD, PhD Research Professor 22.5.2012 Heart and brain/ Veikko Salomaa 1 Veikko Salomaa, MD, PhD Research Professor National Institute for Health
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationObjectives. Falling Down on Warfarin Therapy. CHADS 2 Score. CHADS 2 & CHA 2 DS 2 -VASc Score. HAS-BLED Score 04/08/2014. Real World Application
Falling Down on Warfarin Therapy David Andrew Jacob, PharmD Pharmacy Resident 2013-2014 Dayton VA Medical Center Dayton, Ohio Objectives Describe CHADS 2 score and the decision to anticoagulate patients
More informationNOACs Update PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich
NOACs Update 2016 PD Dr. Jan Steffel Leitender Arzt, Klinik für Kardiologie Co-Leiter Rhythmologie Universitätsspital Zürich Conflict of Interest Statement o o o o Consulting: Amgen, Astra Zeneca, AtriCure,
More informationNew Data Reaffirm Positive Benefit-Risk Balance of Bayer s Xarelto in Patients with Atrial Fibrillation in Daily Clinical Practice
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 12 th Annual Congress of the European Cardiac Arrhythmia Society (ECAS) 2016:
More information